Neoadjuvan Tedavi Prensipleri
Özet
Neoadjuvan tedavi, lokal tedavi yöntemlerinden (genellikle cerrahi) önce uygulanan sistemik ilaç ve radyoterapi süreçlerini kapsayarak modern onkolojide kritik bir rol oynamaktadır. Bu tedavi modelinin temel amacı, tümör hacmini küçülterek başlangıçta opere edilemeyen hastaları cerrahiye uygun hale getirmek, organ fonksiyonlarını korumak ve mikrometastazları erken evrede elimine etmektir. Tümörün tedaviye verdiği yanıtın doğrudan gözlemlenmesi, klinik uzmanlara bir in vivo ilaç duyarlılık testi imkanı sunarak sonraki tedavi adımlarının optimize edilmesine olanak tanır. Klinik araştırmalar anal kanal, rektum, mesane, baş-boyun ve meme kanserleri ile osteosarkom gibi agresif malignitelerde neoadjuvan yaklaşımların sağkalım sürelerini uzattığını ve lokal nüks riskini bariz şekilde düşürdüğünü ortaya koymaktadır. Özellikle anal kanal kanserinde sfinkter fonksiyonlarının korunmasını sağlayarak hastaların yaşam kalitesini artırması, bu yöntemin en somut başarılarındandır.
Neoadjuvant therapy encompasses systemic drug regimens and radiotherapy administered prior to definitive local interventions like surgery, playing a pivotal role in modern oncology. The primary objective of this therapeutic model is to downstage tumor volume, converting unresectable cases into surgically manageable ones, while preserving organ functions and eliminating early micrometastases. Direct observation of the tumor's response provides clinical specialists with an invaluable in vivo drug sensitivity test, allowing for the precise optimization of subsequent therapeutic steps. Clinical research indicates that neoadjuvant approaches significantly prolong survival times and reduce the risk of local recurrence in aggressive malignancies such as anal, rectal, bladder, breast, head and neck cancers, and osteosarcoma. Notably, its capacity to preserve sphincter function in anal canal cancer, thereby enhancing the patient's post-treatment quality of life, represents one of the most substantial milestones of this preoperative methodology.
Referanslar
Imyanitov, Evgeny N., and Grigoriy A. Yanus. "Neoadjuvant therapy: theoretical, biological and medical consideration." Chinese Clinical Oncology 7.6 (2018): 55-55.
Trimble, E. L., et al. "Neoadjuvant therapy in cancer treatment." Cancer 72.S11 (1993): 3515-3524.
Lordick, Florian, and Ines Gockel. "Chances, risks and limitations of neoadjuvant therapy in surgical oncology." Innovative surgical sciences 1.1 (2016): 3-11.
Ma B, Gao P, Wang H, et al. What has preoperative radio(chemo)therapy brought to localized rectal cancer patients in terms of perioperative and long-term outcomes over the past decades? A systematic review and meta-analysis based on 41,121 patients. Int J Cancer 2017; 141:1052.
Semiz HS, Öztop İ. Rektum kanserinde neoadjuvan tedavi. Bilkay Görken İ, editör. Rektum Kanserinin Multidisipliner Tedavisi. 1. Baskı. Ankara: Türkiye Klinikleri; 2020. p.52- 9.
Demiröz, C., & Özşahin, E. M. (2011). Skuamöz Hücreli Baş Boyun Kanserinde Kemoradyoterapi. Uludağ Üniversitesi Tıp Fakültesi Dergisi, 37(1), 61-65.
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls (Accessed on Oct 20, 2022).
Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24:4620.
Grobmyer SR, Maki RG, Demetri GD, et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol 2004; 15:1667.
Acem I, van Houdt WJ, Grünhagen DJ, et al. The role of perioperative chemotherapy in primary high-grade extremity soft tissue sarcoma: a risk-stratified analysis using PERSARC. Eur J Cancer 2022; 165:71.
Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003; 361:1927.
Meeks JJ, Bellmunt J, Bochner BH, et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2012; 62:523.
Pfister C, Gravis G, Fléchon A, et al. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. Eur Urol 2021; 79:214.
Pfister C, Gravis G, Fléchon A, et al. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. J Clin Oncol 2022; 40:2013.
Schwartz GF, Hortobagyi GN. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer 2004; 100:2512.
Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol 2021; 39:1485.
Wilke LG, Nguyen TT, Yang Q, et al. Analysis of the Impact of the COVID-19 Pandemic on the Multidisciplinary Management of Breast Cancer: Review from the American Society of Breast Surgeons COVID-19 and Mastery Registries. Ann Surg Oncol 2021; 28:5535.
Tonneson JE, Hoskin TL, Day CN, et al. Impact of the COVID-19 Pandemic on Breast Cancer Stage at Diagnosis, Presentation, and Patient Management. Ann Surg Oncol 2022; 29:2231.
Koh WJ, Abu-Rustum NR, Bean S, et al. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019; 17:64.
Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev 2010; :CD008285.
Kim YS, Shin SS, Nam JH, et al. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer. Gynecol Oncol 2008; 108:195.
Gupta S, Maheshwari A, Parab P, et al. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial. J Clin Oncol 2018; 36:1548.
Hu, Jianwen, et al. "Survival benefits from neoadjuvant treatment in gastric cancer: a systematic review and meta-analysis." Systematic reviews 11.1 (2022): 1-10.
